UTILITY PATENT APPLICATION TRANSMITTAL

(For new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	P50770X1C1
First Named Inventor	Taylor

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

7. ☒ The Title of the Invention:
MONOCLONAL ANTIBODIES WITH REDUCED IMMUNOGENICITY

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to Deposit Account No. 19-2570
   ☒ General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extensions of time, relating to this application. (37 CFR 1.136(a)(3))
   (Submit an original, and a duplicate for fee processing)

8. ☒ Nucleotide and/or Amino Acid Sequence Submission
   a. ☐ Computer Readable Copy
   b. ☒ Paper Copy (identical to computer copy)
   c. ☐ Statement verifying identity of above copies
   d. ☒ Use the identical computer-readable form filed in Application No. 09/300,970, filed April 28, 1999 as the computer-readable form for the instant application. (37 CFR 1.821(e))

2. ☒ The total fee is calculated as shown below:

Basic Filing fee	$710.00
Total Claims 19 - 20 = 0 x $18	$ .00
Independent Claims 3 - 3 = 0 x $80	$ .00
☐ Multiple Dependent Claim present. $270	
TOTAL FILING FEE	**$710.00**

☒ Cancel in this application original claims 20 to 31 of the prior application before calculating the filing fee.

☒ **Charge $710.00** to the above indicated Deposit Account.

ACCOMPANYING APPLICATION PARTS

9. a. ☐ Information Disclosure Statement (IDS)
    b. ☒ PTO-1449
    c. ☐ Copies of all IDS Citations

10. ☐ Assignment Papers (cover sheet & document(s))

11. ☒ Prior Application is Assigned to:
    SmithKline Beecham Corporation
    (for continuation/divisional with Box 17a completed

3a. ☒ Specification excluding Drawings [Total Pages] 113
3b. ☐ Abstract on a separate sheet [Total Pages]

12. ☐ Preliminary Amendment [Total Pages]

4. ☒ Drawing(s) (35 USC 113) [Total Sheets] 6

13. ☒ Return Receipt Postcard (MPEP 503)
    (Should be specifically itemized)

5. ☒ Declaration and Power of Attorney [Total Pages] 3
   a. ☐ Newly executed (original or copy)
   b. ☒ Copy from a prior application (37 CFR 1.63(d))
      (for continuation/divisional with Box 17a completed)
   c. ☐ Unsigned Declaration
      [Note Box 6 below]
      i. ☐ DELETION OF INVENTOR(S)
      Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).

14. ☐ Certified Copy of Priority Document(s)
    (if foreign priority is claimed)

15. ☒ Transfer all references cited by Applicants or by the Examiner from the parent Application Serial No. 09/300,970 filed April 28, 1999. A PTO-1449 listing the references is enclosed.

16. ☐ Other: _____

6. ☒ Incorporation By Reference *(useable if Box 5b is checked)*
   The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

17. ☒ Priority Information, *check appropriate box and supply the requisite information*

a. The accompanying application is a   ☒ Continuation   ☐ Divisional   ☐ Continuation-in-part (CIP)
   of prior application **Serial No: 09/300,970** filed **April 28, 1999**.

b. ☒ Benefit is claimed under Title 35, United States Code, Section 119(e) of the following Provisional Applications:
   Application No. **60/083,367** filed **April 28, 1998**.

c. ☒ Please amend the specification by inserting before the first line the sentence: (37 CFR 1.78)
   This is a continuation of application Serial No. **09/300,970** filed **April 28, 1999**, which claims the benefit of U.S. Provisional Application No. **60/083,367**, filed **April 28, 1998**.

18. CORRESPONDENCE ADDRESS

Address	GLAXOSMITHKLINE Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939
Telephone	(610) 270-5096 Fax (610) 270-5090

19. RESPECTFULLY SUBMITTED,

Signature	
Name	**Kirk Baumeister**
Registration No.	33,833